Table 2.

Pituitary hormone levels of MPHD in different groups

	Normal range	PSIS	Hypoplasia	Normal	Tumor-survivor	P1	P2	P3	P4	P5	P6
FT4	12–22 pmol/L	9.82 ± 2.75	12.31 ± 3.07	12.75 ± 2.07	11.23 ± 3.58	≤0.001	0.002	0.008	0.682	0.200	0.198
TSH	0.27–4.2 μIU/ml	1.03 ± 1.08	1.38 ± 1.47	2.49 ± 1.53	0.76 ± 1.15	0.193	≤0.001	0.149	0.056	0.045	≤0.001
IGF-1	111–555 ng/ml	33.60 ± 16.44	45.49 ± 44.67	41.69 ± 22.29	48.57 ± 34.19	0.039	0.159	≤0.001	0.800	0.737	0.543
GH peak	> 10.00 ng/ml	1.37 ± 1.78	1.27 ± 1.52	3.36 ± 1.79	0.53 ± 0.52	0.801	≤0.001	≤0.001	0.002	0.002	≤0.001
COR	172–497 nmol/l	110.88 ± 103.05	222.73 ± 124.03	215.00 ± 217.30	134.48 ± 171.48	≤0.001	0.009	0.294	0.896	0.025	0.193
ACTH	7.2–63.3 pg/ml	27.50 ± 20.72	25.05 ± 14.64	34.61 ± 59.35	7.19 ± 8.63	0.587	0.423	≤0.001	0.458	≤0.001	≤0.001
FSH peaka	mIU/ml	1.28 ± 1.36 b	1.28 ± 1.05c	/d	0.22 ± 0.21e	> 0.99	/	0.019	/	0.006	/
LH peaka	mIU/ml	0.36 ± 0.58	1.03 ± 1.45	/	0.14 ± 0.08	0.038	/	0.242	/	0.069	/
Ta	ng/ml	0.26 ± 0.65	0.44 ± 0.93	/	0.45 ± 0.69	0.507	/	0.429	/	0.979	/

P1: P-value between PSIS-group vs Hypoplasia-group. P2: P-value between PSIS-group vs Normal-group. P3: PSIS-group vs Tumor-survivor-group. P4: P-value between Hypoplasia-group VS Normal-group. P5: P-value between Hypoplasia -group VS Tumor-survivor-group. P6: P-value between Normal-group VS Tumor-survivor-group

PSIS pituitary stalk interruption syndrome, FT4 free thyroxine, TSH thyroid-stimulating hormone, IGF-1 insulin growth factor 1, GH growth hormone, COR cortisol, ACTH adrenocorticotropic hormone, FSH follicle-stimulation hormone, LH luteinizing hormone, T testosterone

^aPatients whose referral age was above 12 years and only analyzed data of male patients, for the number of female patients was small and could not be analyzed

^bN = 33

^cN = 9

^dN = 2

^eN = 10